Presentations
Bosch R., Snelder N. Linking the 4GI glucose homeostasis and Hall body composition models to quantify weight loss effects of GLP-1R agonists, and body weight effects on insulin sensitivity. ACoP 2022. [Link to publication]
Mahar K.M., Goulooze S.C., Yang S., Mesic E., Beerahee M., Post T.M. Population pharmacokinetics of daprodustat across five phase 2b/3 studies in chronic kidney disease (CKD) patients with anemia. ACoP 2022. [Link to publication]
Noort van N., Berg van den P., Post T.M., Beerahee M., Mahar K.M., Yang S. Population Dose-Hgb modelling of daprodustat across five Phase 3 studies in chronic kidney disease (CKD) patients with anemia. ACoP 2022. [Link to publication]
Goulooze S.C., Noort van N., Berg van den P., Yang S., Beerahee M., Mahar K.M., Post T.M. Innovative adaptive dose simulations in NONMEM to allow simulation-based model evaluation of titration-based dosing, applied to a population doe-hemoglobin model for daprodustat. ACoP 2022. Link to publication
Bosch R. Successful prediction of continuous glucose dynamics and HbA1c response to the GLP-1 and glucagon co-agonist cotadutide using the 4GI- HbA1c systems model The G lucose- G LP-1- G lucagon- G IP- I nsulin ( 4GI ) model. ASCPT 2021. (poster and lecture)
Berg van der P., Post T., Ahsman M., Berg van der P., Hooijmaijers R., Snelder N., Yang S., ., Vasist L., Mahar K., Visser S. Population Dose-Response Analysis of Hemoglobin Data From Global Phase 2 and Japanese Phase 3 Studies With Daprodustat in Chronic Kidney Disease Patients With Anemia Following Once Daily (OD) or 3x…
Mahar K., Post T., Ahsman M., Berg van der P., Hooijmaijers R., Snelder N., Vasist L., Visser S. Population Pharmacokinetic Analysis of Daprodustat in Healthy Volunteers (HV), Global Phase 2 and Japanese Phase 3 Studies in Chronic Kidney Disease Patients with Anemia Following Once Daily (QD) or 3x Weekly (TIW) Administration. ASCPT 2021.
Snelder N., Post T., Berg van der P., Hooijmaijers R., Ahsman M., Vasist L., Mahar K., Visser S. Population Pharamcokinetic/pharmacodynamics (PKPD) Analysis of EPO during daprodustat treatment in healthy volunteers (HV) and chronic kidney disease (CKD) patients with Anemia. ASCPT 2021.
Schoemaker R., Fidler M., Laveille C., Wilkins J.J., Hooijmaijers R., Post T.M., Trame M.N., Xiong Y., Wang W. Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr. PAGE, 2019. [Link to publication]
Grothey A., Hoefman S., Ruppert M., Vis P., Zisowsky J., Cutsem E., Dochy E.v. Fiala-buskies S., Cleton A., Ploeger B. Exploration of efficacious alternative regorafenib regimens to manage hand − foot skin reaction. ESMO, 2019.